Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD (2017)

Publication Type: Journal article

Publication year: 2017

Journal

BMC Nephrology BMC

Book Volume: 18

Pages Range: 24

Journal Issue: 1

DOI: 10.1186/s12882-017-0444-6

Abstract

Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse.FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400-600 ?g/L) or lower (100-200 ?g/L) ferritin values, or oral iron.Mean (SD) eGFR at baseline was 34.9 (11.3), 32.8 (10.8) and 34.2 (12.3) mL/min/1.73 m(2) in the high ferritin FCM (n = 97), low ferritin FCM (n = 89) and oral iron (n = 167) groups, respectively. Corresponding values at month 12 were 35.6 (13.8), 32.1 (12.7) and 33.4 (14.5) mL/min/1.73 m(2). The pre-specified endpoint of mean (SE) change in eGFR from baseline to month 12 was +0.7 (0.9) mL/min/1.73 m(2) with high ferritin FCM (p = 0.15 versus oral iron), -0.9 (0.9) mL/min/1.73 m(2) with low ferritin FCM (p = 0.99 versus oral iron) and -0.9 (0.7) mL/min/1.73 m(2) with oral iron. No significant association was detected between quartiles of FCM dose, change in ferritin or change in TSAT versus change in eGFR. Dialysis initiation was similar between groups. Renal adverse events were rare, with no indication of between-group differences.Intravenous FCM at doses that maintained ferritin levels of 100-200 ?g/L or 400-600 ?g/L did not negatively impact renal function (eGFR) in patients with ND-CKD over 12 months versus oral iron, and eGFR remained stable. These findings show no evidence of renal toxicity following intravenous FCM over a 1-year period.ClinicalTrials.gov NCT00994318 (first registration 12 October 2009).

Authors with CRIS profile

Kai-Uwe Eckardt Department of Medicine 4 – Nephrology and Hypertension

Involved external institutions

Vifor Pharma AG CH Switzerland (CH) DaVita Inc. US United States (USA) (US) University of Groningen / Rijksuniversiteit Groningen NL Netherlands (NL) Kantonsspital Aarau AG CH Switzerland (CH) King's College Hospital (KCH) GB United Kingdom (GB)

How to cite

APA:

Macdougall, I.C., Bock, A.H., Carrera, F., Eckardt, K.-U., Gaillard, C., Van Wyck, D.,... Roger, S.D. (2017). Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. BMC Nephrology, 18(1), 24. https://dx.doi.org/10.1186/s12882-017-0444-6

MLA:

Macdougall, Iain C., et al. "Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial." BMC Nephrology 18.1 (2017): 24.

BibTeX: Download